Antimicrobial Drug Approval May Be Speeded By Enhanced Preclinical Studies
Executive Summary
FDA should emphasize the use of preclinical studies to speed the approval of drugs that address antimicrobial resistance problems, an interagency task force report suggests.
You may also be interested in...
Antimicrobials Labeling Rule Should Allow "Appropriate Use," PhRMA Says
FDA's proposed rule on labeling requirements for systemic antimicrobials should allow for "appropriate treatment" of infections that are suspected to be caused by susceptible microorganisms, the Pharmaceutical Research & Manufacturers of America said in comments to the agency.
Antimicrobials Labeling Rule Should Allow "Appropriate Use," PhRMA Says
FDA's proposed rule on labeling requirements for systemic antimicrobials should allow for "appropriate treatment" of infections that are suspected to be caused by susceptible microorganisms, the Pharmaceutical Research & Manufacturers of America said in comments to the agency.
In Vitro Data Not Relevant To Clinical Use Should Be Cleared From Label - FDA
Sponsors would have one year to remove in vitro data that has not been clinically validated from labeling, under proposed FDA guidelines for simplified prescription drug labeling.